Business
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 \nTopline results continue to be expected in the first half of 2025 for the Phase 2b CORAL trial in chronic cough in IPF \nIND cleared with the FDA for planned Phase 1b trial to evaluate respiratory physiology in IPF patients with varying disease severity\nManagement to host a conference call and webcast today at 4:30 p.m. ET \nNEW HAVEN, Conn., May 7, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter ended March 31, 2024, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nTrevi reaffirms guidance for clinical development milestones, progressing Haduvio in chronic cough indications\"I am pleased with the progress across all our clinical trials, which continue to remain on track with our guidance,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"During the quarter, we continued site activations and recruitment across our clinical trials and, with the clearance of our IND, we are moving towards initiating our planned respiratory physiology trial. We look forward to reporting data from our ongoing trials beginning in the second half of this year. The chronic cough markets in both IPF and refractory chronic cough are significant and currently have no approved therapies in the U.S. We believe our differentiated central and peripheral mechanism of action has the potential to offer an important therapy for these patients.\" \nKey Business Updates\nPhase 2a RIVER trial for the treatment of RCC, in which we expect to enroll approximately 60 patients, now has all sites activated and enrollment is progressing. In line with our current guidance, we expect topline data in the second half of 2024.Phase 2b CORAL trial for the treatment of chronic cough in IPF, in which we expect to enroll approximately 160 patients, continues enrollment, and we expect the sample size re-estimation to occur in the second half of 2024 when 50% of the patients are evaluable for the ...